open access

Vol 1, No 2 (2005)
Review paper
Published online: 2005-06-08
Get Citation

Prostate cancer chemotherapy

Maciej Krzakowski
Onkol. Prak. Klin 2005;1(2):72-75.

open access

Vol 1, No 2 (2005)
REVIEW ARTICLES
Published online: 2005-06-08

Abstract

Median survival of hormone-refractory prostate cancer patients is in a range of 10–12 months and a search for new options of systemic therapy is required. Until recently, the vast majority of cytotoxic agents provided low response rate and produced unsatisfactory palliation of symptoms. A new stage in prostate cancer chemotherapy is related to trials with the use of taxoids. Although these trials documented the superiority of docetaxel-based therapy, mitoxantrone combined with hydrocortisone remains standard therapeutic option, whereas the use of docetaxel should be limited to patients without cardiovascular comorbidities and risk factors for neurotoxicity.

Abstract

Median survival of hormone-refractory prostate cancer patients is in a range of 10–12 months and a search for new options of systemic therapy is required. Until recently, the vast majority of cytotoxic agents provided low response rate and produced unsatisfactory palliation of symptoms. A new stage in prostate cancer chemotherapy is related to trials with the use of taxoids. Although these trials documented the superiority of docetaxel-based therapy, mitoxantrone combined with hydrocortisone remains standard therapeutic option, whereas the use of docetaxel should be limited to patients without cardiovascular comorbidities and risk factors for neurotoxicity.
Get Citation

Keywords

prostate cancer; chemotherapy; taxoids; docetaxel

About this article
Title

Prostate cancer chemotherapy

Journal

Oncology in Clinical Practice

Issue

Vol 1, No 2 (2005)

Article type

Review paper

Pages

72-75

Published online

2005-06-08

Bibliographic record

Onkol. Prak. Klin 2005;1(2):72-75.

Keywords

prostate cancer
chemotherapy
taxoids
docetaxel

Authors

Maciej Krzakowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl